This study investigated Complex Innovative Design (CID) trials in cancer research through a detailed survey of professionals including researchers, clinicians, and industry experts. The survey combined qualitative and quantitative questions to provide a broad perspective on CID trials' effectiveness, the challenges encountered, and the impact on patient outcomes. The results revealed that CID trials are generally seen as beneficial in accelerating drug development, with 55.2% of respondents finding them either extremely or very effective. Despite these positive perceptions, the survey highlighted significant challenges such as data management, coordination among stakeholders, and compliance with regulatory standards. Qualitative feedback identified specific issues like the complexity of trial design and regulatory hurdles. The study also examined how CID trials influence patient outcomes, noting advancements in personalized treatment but underscoring the necessity for stringent safety monitoring. By integrating both types of data, the study offered a comprehensive view of CID trials and proposed recommendations to refine trial methodologies and regulatory frameworks, aiming to enhance future cancer research and drug development efforts